Carnot OPALE


The OPALE Carnot Institute is a preferred partner to the healthcare Industry for research and development of innovative solutions aimed at diagnostic, treatment and follow-up of patients with leukemia and related diseases, together the blood cancer with the highest mortality rate, also the first child cancer.
Thanks to its 692 engaged staff, the Institute offers partner companies an easy, quick and efficient access to internationally unmatched R&D expertise and specialized means for the acceleration, together, of innovation along the R&D value chain.


The consortium for Leukemia and diseases partnering research

OPALE offers its partners a unique continuum in the leukemia field: an unparalleled array of competencies, from scientific innovation to industrial and medical valorization.

Adressed economic sectors

  • Drugs
  • Healthtech
  • Biotechnologies
  • In vitro diagnostic

Through its 28 entities spread over the French territory, OPALE is a national consortium gathering most of France’s academic research and development strenghts in the leukemia and related diseases field: every other year, they produce more than 368 papers in top-tier peer-reviewed medical journals and there is a portfolio of close to 43 active patents.


OPALE’s state-of-the-art equipments, platforms and scientific assets include:

  • Data and biological resources: Clinical databases / Biological collections / Biobanks
  • Methodology platforms
  • Clinical development platforms
  • Biology research platforms: Genomics / In vitro/in vivo screening and tests / Animal models / Immuno-monitoring / Bioinformatics and in silico research
  • Drug design platforms: Drugs / Antibodies / Advanced therapy medicinal products
  • Partnering platforms: Startups incubator / Industry advisory board

The OPALE consortium, organized as a one-stop shop hosted by the THEMA University-Hospital Institute on the Saint-Louis University Hospital site, Paris, France, benefits from top level scientific, strategic and operational management bodies and from a strong support from its entities’ governing institutions: